Ropinirole for the treatment of early Parkinson's disease

C. H. Adler, K. D. Sethi, R. A. Hauser, T. L. Davis, J. P. Hammerstad, J. Bertoni, R. L. Taylor, J. Sanchez-Ramos, C. F. O'Brien

Research output: Contribution to journalArticle

260 Scopus citations

Abstract

A prospective, randomized, placebo-controlled, double-blind, parallel- group, 6-month study assessed the efficacy and safety of ropinirole, a nonergoline D2-dopamine agonist, in patients with early Parkinson's disease (n = 241; Hoehn and Yahr stages I to III) with limited or no prior dopaminergic therapy. Patients (mean age, 62.8 years), stratified by concomitant use of selegiline, were randomized to ropinirole (n = 116) or placebo (n = 125). The starting dose of ropinirole was 0.25 mg tid with titration to at least 1.5 mg tid (maximum dose, 8 mg tid). Primary efficacy endpoint was the percentage improvement in Unified Parkinson's Disease Rating Scale (UPDRS) motor score. Ropinirole-treated patients had a significantly greater percentage improvement in UPDRS motor score than patients who received placebo (+24% vs -3%; p < 0.001). Ropinirole was well tolerated and patient withdrawals were infrequent. Most adverse experiences were related to peripheral dopaminergic activity. Ropinirole monotherapy is an effective and well-tolerated therapeutic option for treatment of early Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)393-399
Number of pages7
JournalNeurology
Volume49
Issue number2
DOIs
Publication statusPublished - Jan 1 1997

    Fingerprint

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Adler, C. H., Sethi, K. D., Hauser, R. A., Davis, T. L., Hammerstad, J. P., Bertoni, J., ... O'Brien, C. F. (1997). Ropinirole for the treatment of early Parkinson's disease. Neurology, 49(2), 393-399. https://doi.org/10.1212/WNL.49.2.393